Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Jul 1;150(7):332.
doi: 10.1007/s00432-024-05827-x.

Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116)

Dominik Paul Modest  1   2 , Volker Heinemann  3   4 , Philipp Schütt  5 , Stefan Angermeier  6 , Mike Haberkorn  7 , Oliver Waidmann  8 , Ullrich Graeven  9 , Kai Wille  10 , Volker Kunzmann  11 , Larissa Henze  12 , Christian Constantin  13 , Maike de Wit  14 , Claudio Denzlinger  15 , Alexej Ballhausen  16 , Annika Kurreck  16 , Ivan Jelas  16 , Annabel Helga Sophie Alig  16 , Arndt Stahler  16 , Sebastian Stintzing  16   3 , Helmut Oettle  17
Affiliations
Randomized Controlled Trial

Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116)

Dominik Paul Modest et al. J Cancer Res Clin Oncol. .

Abstract

Purpose: In patients with metastatic pancreatic cancer, after failure of gemcitabine/nab-paclitaxel, this trial compares the efficacy of second-line therapy with FOLFIRI vs. OFF (1:1 randomisation) with cross-over to the vice-versa regimen as third-line therapy.

Patients and methods: The primary endpoint was PFS (progression-free survival: time from randomization until progression or death) of second-line therapy. The trial aimed to demonstrate non-inferiority of FOLFIRI vs OFF (non-inferiority margin of a hazard ratio (HR) of 1.5, power of 80% and a significance level of 5%, 196 events needed). Secondary endpoints included overall survival (OS), progression-free survival of third-line therapy and safety. The trial is registered with EudraCT Nr. 2016-004640-11.

Results: The trial was terminated with 60 evaluable (37 with FOLFIRI, 23 with OFF) patients due to insufficient recruitment. PFS of second-line therapy was 2.4 (95% CI 2.3-2.6) months with FOLFIRI vs 2.4 (95% CI 2.2-2.7) months with OFF (HR: 0.80, 95% CI 0.45-1.42, P = 0.43). OS was comparable between the arms (HR: 0.95, 95% CI 0.54-1.66), P = 0.84). Only 4 out of 28 (14%) patients receiving third-line therapy achieved a disease control (partial remission or stable disease). Both second-line regimens were well tolerated without new or unexpected safety signals being observed.

Conclusion: The exploratory analysis of this early terminated trial suggests that FOLFIRI and OFF have similar efficacy ant toxicity as second-line therapy of PDAC after failure of gemcitabine/nab-paclitaxel. Third-line therapy regardless of regimen does not provide satisfactory efficacy in this sequential treatment algorithm.

Keywords: Chemotherapy; FOLFIRI; Fluoropyrimidine; Metastatic; Oxaliplatin; Pancreatic cancer.

PubMed Disclaimer

Conflict of interest statement

UG: honoraria/Advisory role: Boehringer INgelheim, AstraZeneca, Bristol-Myers-Squibb, MSD, Sanofi, Fujifilm, Novartis, Amgen. Travel support: GSK, Boehringer-Ingelheim, Amgen, Merck KGaA AHSA: Honoraria: MSD, Merck CD: Honoraria: Abbvie, Bayer, Celgene, Incyte, Janssen, Novartis HO: research funding: Bristol, Servier SS: honoraria: Amgen, AstraZeneca, Bayer, BMS, ESAI, Leo Pharma, Lilly, Merck, MSD, PierreFabre, Roche, Sanofi, Servier, Taiho, Takeda. Research funding: Merck, Pierre Fabre, Servier, Roche, MSD, Novartis, Biontech, ISofol, Mirati, Amgen AK: Honoraria: Merck AS: Honoraria: Roche, Servier, Taiho, Amgen, Pfizer, Lilly, Merck OW: honoraria: Amgen, Bayer, BMS, Celgene, Eisai, Incyte, Ipsen, MerckSerono, MSD, Novartis, Roche, Servier, AstraZeneca. Travel support: Abbvie, Bayer, BMS, Gilead, Ipsen, Medac, Merck. research funding (inst): Merck VH: Honoraria: Merck, Amgen, Roche, Sanofi, Sirtex, Servier, Pfizer, Pierre-Fabre, AstraZeneca, BMS; MSD, Novartis, Boehringer-INgelheim, Celgene, Terumo, Oncosil, Seagen. Support to institution: Merck, Amgen, Roche, Sanofi, Pfizer, Boeringer-Ingelheim, Sirtex, Servier DPM: Honoraria: Merck, Amgen, Servier, AstraZenenca, MSD, Sanofi, Lilly, Pierre-Fabre, Seagen, Onkowissen, IKF, MCI-Deutschland, Jörg Eickeler Veranstaltungen, Taiho, Takeda, Medscape, Cor2ED, G1, 21up, FOMF, Aptitude, GSK. Travel support: Merck, Amgen, Servier. Research funding (inst): Servier, Amgen

Figures

Fig. 1
Fig. 1
Study design. FOLFIRI denotes irinotecan, 5-fluorouracil and folinic acid. OFF denotes 5-fluorouracil, folinic acid and oxaliplatin
Fig. 2
Fig. 2
Consort diagram. FOLFIRI denotes irinotecan, 5-fluorouracil and folinic acid. OFF denotes 5-fluorouracil, folinic acid and oxaliplatin
Fig. 3
Fig. 3
Kaplan–Meier estimates of the full analysis set for PFS, PFS3, TTFS and OS. Indicated hazard ratios derived from Cox regression testing. P-values derived from log rank tests. A Kaplan–Meier estimate of progression-free survival of second-line therapy (primary endpoint), B Kaplan–Meier estimate of progression-free survival of third-line therapy (secondary endpoint), C Kaplan–Meier estimate of time to failure of strategy (secondary endpoint), D Kaplan–Meier estimate of overall survival (secondary endpoint),
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013;14(1):29–37. doi: 10.1016/S1470-2045(12)70477-1. - DOI - PubMed
    1. Carrato A, Pazo-Cid R, Macarulla T, et al. Sequential nab-paclitaxel/gemcitabine followed by modified FOLFOX for first-line metastatic pancreatic cancer The SEQUENCE trial. J Clin Oncol. 2022;40:4022. doi: 10.1200/JCO.2022.40.16_suppl.4022. - DOI
    1. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–1825. doi: 10.1056/NEJMoa1011923. - DOI - PubMed
    1. Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or Gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395–2406. doi: 10.1056/NEJMoa1809775. - DOI - PubMed
    1. Ducreux M, Cuhna AS, Caramella C, et al. Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v56–68. doi: 10.1093/annonc/mdv295. - DOI - PubMed

Publication types

MeSH terms

Supplementary concepts